{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:00:25Z","timestamp":1791975625388,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2018ZC0233"],"award-info":[{"award-number":["ZR2018ZC0233"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013072","name":"Major Science and Technology Project of Hainan Province","doi-asserted-by":"publisher","award":["2015ZDJS04001"],"award-info":[{"award-number":["2015ZDJS04001"]}],"id":[{"id":"10.13039\/501100013072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21629201"],"award-info":[{"award-number":["21629201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.apsb.2020.01.014","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T11:36:59Z","timestamp":1580125019000},"page":"1669-1679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["First small-molecule PROTACs for G protein-coupled receptors: inducing 1A-adrenergic receptor degradation"],"prefix":"10.1016","volume":"10","author":[{"given":"Zhenzhen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaopan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lupei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2020.01.014_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-3565(24)29397-6","article-title":"\u03b11-Adrenergic receptors: new insights and directions","volume":"298","author":"Piascik","year":"2001","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2020.01.014_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0014-2999(99)00222-8","article-title":"\u03b11-Adrenoceptor subtypes","volume":"375","author":"Zhong","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2020.01.014_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0163-7258(03)00033-0","article-title":"Recent advances in \u03b11-adrenoceptor pharmacology","volume":"98","author":"Koshimizu","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2020.01.014_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00018-009-0174-4","article-title":"Subtypes of functional \u03b11-adrenoceptor","volume":"67","author":"Docherty","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2020.01.014_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/ncpuro1276","article-title":"Subtypes of \u03b11-adrenoceptors in BPH: future prospects for personalized medicine","volume":"6","author":"Kojima","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.apsb.2020.01.014_bib6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1476-5381.1996.tb15742.x","article-title":"Quantification and distribution of \u03b11-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue","volume":"119","author":"Nasu","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2020.01.014_bib7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/pros.20399","article-title":"Quantification of \u03b11-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients","volume":"66","author":"Kojima","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.apsb.2020.01.014_bib8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/ijc.27711","article-title":"Global estimates of cancer prevalence for 27 sites in the adult population in 2008","volume":"132","author":"Bray","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2020.01.014_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1023\/A:1026057402945","article-title":"The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer","volume":"253","author":"Chatterjee","year":"2003","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.apsb.2020.01.014_bib10","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/ijms17081339","article-title":"The role of \u03b11-adrenoceptor antagonists in the treatment of prostate and other cancers","volume":"17","author":"Batty","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2020.01.014_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10799890601087487","article-title":"Dominance of the \u03b11B-adrenergic receptor and its subcellular localization in human and TRAMP prostate cancer cell lines","volume":"27","author":"Shi","year":"2007","journal-title":"J Recept Signal Transduct Res"},{"key":"10.1016\/j.apsb.2020.01.014_bib12","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1172\/JCI16293","article-title":"\u03b11-Adrenergic receptors activate Ca2+-permeable cationic channels in prostate cancer epithelial cells","volume":"111","author":"Thebault","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2020.01.014_bib13","first-page":"4550","article-title":"Suppression of human prostate cancer cell growth by \u03b11-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis","volume":"60","author":"Kyprianou","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2020.01.014_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2020.01.014_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.01.014_bib16","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACS: new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.apsb.2020.01.014_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.01.014_bib18","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.01.014_bib19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.apsb.2020.01.014_bib20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem Biol"},{"key":"10.1016\/j.apsb.2020.01.014_bib21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2020.01.014_bib22","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1021\/ja100691p","article-title":"Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins","volume":"132","author":"Itoh","year":"2010","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2020.01.014_bib23","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.bmcl.2011.11.086","article-title":"Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy","volume":"22","author":"Demizu","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.01.014_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in\u00a0vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2020.01.014_bib25","doi-asserted-by":"crossref","first-page":"6768","DOI":"10.1016\/j.bmc.2011.09.041","article-title":"Design, synthesis and biological evaluation of nuclear receptor-degradation inducers","volume":"19","author":"Itoh","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2020.01.014_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.471","article-title":"Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway","volume":"5","author":"Ohoka","year":"2014","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2020.01.014_bib27","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1021\/acs.jmedchem.5b01843","article-title":"Discovery of the first environment-sensitive near-infrared (NIR) fluorogenic ligand for \u03b11-adrenergic receptors imaging in\u00a0vivo","volume":"59","author":"Ma","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.01.014_bib28","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/ml5004298","article-title":"Discovery of quinazoline-based fluorescent probes to \u03b11-adrenergic receptors","volume":"6","author":"Zhang","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.01.014_bib29","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras\u00a0(PROTACs) in \u2018beyond rule-of-five' chemical space: recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.01.014_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDBI-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.01.014_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.apsb.2020.01.014_bib32","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1593\/neo.07475","article-title":"Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle","volume":"9","author":"Lin","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.apsb.2020.01.014_bib33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/pros.23167","article-title":"Relative cytotoxic potencies and cell death mechanisms of \u03b11-adrenoceptor antagonists in prostate cancer cell lines","volume":"76","author":"Forbes","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.apsb.2020.01.014_bib34","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/pros.21313","article-title":"Anti-angiogenic effects and mechanism of prazosin","volume":"71","author":"Liao","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.apsb.2020.01.014_bib35","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1517\/14728222.2011.641534","article-title":"Advances in the design and synthesis of prazosin derivatives over the last ten years","volume":"15","author":"Desiniotis","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.apsb.2020.01.014_bib36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1940-6207.CAPR-10-0189","article-title":"Naftopidil, a selective \u03b11-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma","volume":"4","author":"Hori","year":"2011","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.apsb.2020.01.014_bib37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.urolonc.2007.02.010","article-title":"Doxazosin-induced clusterin expression and apoptosis in prostate cancer cells","volume":"25","author":"Youm","year":"2007","journal-title":"Urol Oncol"},{"key":"10.1016\/j.apsb.2020.01.014_bib38","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1464-410x.2000.00607.x","article-title":"Doxazosin: a new cytotoxic agent for prostate cancer?.","volume":"85","author":"Cal","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.apsb.2020.01.014_bib39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.pcan.4500561","article-title":"Induction of prostate apoptosis by \u03b11-adrenoceptor antagonists: mechanistic significance of the quinazoline component","volume":"5","author":"Anglin","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.apsb.2020.01.014_bib40","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/01.ju.0000042453.12079.77","article-title":"Anoikis induction by quinazoline based \u03b11-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2","volume":"169","author":"Keledjian","year":"2003","journal-title":"J Urol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383519313188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383519313188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:44:56Z","timestamp":1761929096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383519313188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2211383519313188"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2020.01.014","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First small-molecule PROTACs for G protein-coupled receptors: inducing \u03b11A-adrenergic receptor degradation","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2020.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}